Is BRNS or ALZN more profitable?

Barinthus Biotherapeutics' return on equity of -59.15% beat Alzamend Neuro's return on equity. Company Net Margins Return on Equity Return on Assets Barinthus Biotherapeutics N/A -59.15% -43.80% Alzamend Neuro N/A -277.74% -200.07%

Is ALZN or EVAX more profitable?

Evaxion A/S's return on equity of -73.56% beat Alzamend Neuro's return on equity. Company Net Margins Return on Equity Return on Assets Alzamend Neuro N/A -277.74% -200.07% Evaxion A/S N/A -73.56% -37.45%

Do analysts recommend TXMD or ALZN?

Alzamend Neuro has a consensus price target of $28.00, indicating a potential upside of 1,831.03%. Given Alzamend Neuro's stronger consensus rating and higher probable upside, analysts clearly believe Alzamend Neuro is more favorable than TherapeuticsMD. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TherapeuticsMD 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Alzamend Neuro 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is HOWL or ALZN more profitable?

Werewolf Therapeutics' return on equity of -166.99% beat Alzamend Neuro's return on equity. Company Net Margins Return on Equity Return on Assets Werewolf Therapeutics N/A -166.99% -59.88% Alzamend Neuro N/A -277.74% -200.07%

Alzamend Neuro (ALZN) Competitors

$1.44 -0.02 (-1.37%)

As of 12:29 PM Eastern

Compare

ALZN vs. BRNS, EVAX, TXMD, HOWL, and AYTU

Should you buy Alzamend Neuro stock or one of its competitors? Alzamend Neuro's main competitors and comparable companies include Barinthus Biotherapeutics (BRNS), Evaxion A/S (EVAX), TherapeuticsMD (TXMD), Werewolf Therapeutics (HOWL), and Aytu BioPharma (AYTU). Companies are selected based on similarities in market, industry, and size.

How does Alzamend Neuro compare to Barinthus Biotherapeutics?

Barinthus Biotherapeutics (NASDAQ:BRNS) and Alzamend Neuro (NASDAQ:ALZN) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, profitability, institutional ownership, analyst recommendations, valuation, dividends, media sentiment and risk.

Barinthus Biotherapeutics' return on equity of -59.15% beat Alzamend Neuro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Barinthus Biotherapeutics	N/A	-59.15%	-43.80%
Alzamend Neuro	N/A	-277.74%	-200.07%

25.2% of Barinthus Biotherapeutics shares are owned by institutional investors. Comparatively, 49.6% of Alzamend Neuro shares are owned by institutional investors. 8.5% of Barinthus Biotherapeutics shares are owned by insiders. Comparatively, 1.4% of Alzamend Neuro shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Alzamend Neuro has lower revenue, but higher earnings than Barinthus Biotherapeutics. Barinthus Biotherapeutics is trading at a lower price-to-earnings ratio than Alzamend Neuro, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Barinthus Biotherapeutics	$14.97M	1.59	-$66.43M	-$1.03	N/A
Alzamend Neuro	N/A	N/A	-$8.77M	-$2.90	N/A

In the previous week, Barinthus Biotherapeutics had 1 more articles in the media than Alzamend Neuro. MarketBeat recorded 1 mentions for Barinthus Biotherapeutics and 0 mentions for Alzamend Neuro. Barinthus Biotherapeutics' average media sentiment score of 1.50 beat Alzamend Neuro's score of 0.00 indicating that Barinthus Biotherapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Barinthus Biotherapeutics	Very Positive
Alzamend Neuro	Neutral

Barinthus Biotherapeutics currently has a consensus target price of $4.00, indicating a potential upside of 584.93%. Alzamend Neuro has a consensus target price of $28.00, indicating a potential upside of 1,831.03%. Given Alzamend Neuro's higher probable upside, analysts clearly believe Alzamend Neuro is more favorable than Barinthus Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Barinthus Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Alzamend Neuro	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Barinthus Biotherapeutics has a beta of -0.39, indicating that its stock price is 139% less volatile than the broader market. Comparatively, Alzamend Neuro has a beta of 0.16, indicating that its stock price is 84% less volatile than the broader market.

Summary

Barinthus Biotherapeutics beats Alzamend Neuro on 7 of the 12 factors compared between the two stocks.

How does Alzamend Neuro compare to Evaxion A/S?

Alzamend Neuro (NASDAQ:ALZN) and Evaxion A/S (NASDAQ:EVAX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership and profitability.

49.6% of Alzamend Neuro shares are held by institutional investors. Comparatively, 11.0% of Evaxion A/S shares are held by institutional investors. 1.4% of Alzamend Neuro shares are held by insiders. Comparatively, 41.6% of Evaxion A/S shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Evaxion A/S has higher revenue and earnings than Alzamend Neuro. Evaxion A/S is trading at a lower price-to-earnings ratio than Alzamend Neuro, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alzamend Neuro	N/A	N/A	-$8.77M	-$2.90	N/A
Evaxion A/S	$7.53M	3.33	-$7.71M	-$1.47	N/A

In the previous week, Evaxion A/S had 1 more articles in the media than Alzamend Neuro. MarketBeat recorded 1 mentions for Evaxion A/S and 0 mentions for Alzamend Neuro. Alzamend Neuro's average media sentiment score of 0.00 equaled Evaxion A/S'saverage media sentiment score.

Company	Overall Sentiment
Alzamend Neuro	Neutral
Evaxion A/S	Neutral

Alzamend Neuro has a beta of 0.16, suggesting that its share price is 84% less volatile than the broader market. Comparatively, Evaxion A/S has a beta of 0.29, suggesting that its share price is 71% less volatile than the broader market.

Evaxion A/S's return on equity of -73.56% beat Alzamend Neuro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alzamend Neuro	N/A	-277.74%	-200.07%
Evaxion A/S	N/A	-73.56%	-37.45%

Alzamend Neuro currently has a consensus target price of $28.00, suggesting a potential upside of 1,831.03%. Evaxion A/S has a consensus target price of $11.00, suggesting a potential upside of 265.33%. Given Alzamend Neuro's higher probable upside, analysts clearly believe Alzamend Neuro is more favorable than Evaxion A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alzamend Neuro	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Evaxion A/S	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Evaxion A/S beats Alzamend Neuro on 10 of the 13 factors compared between the two stocks.

How does Alzamend Neuro compare to TherapeuticsMD?

TherapeuticsMD (NASDAQ:TXMD) and Alzamend Neuro (NASDAQ:ALZN) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends, media sentiment and valuation.

TherapeuticsMD has higher revenue and earnings than Alzamend Neuro. Alzamend Neuro is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TherapeuticsMD	$3.02M	8.05	-$570K	$0.06	35.00
Alzamend Neuro	N/A	N/A	-$8.77M	-$2.90	N/A

TherapeuticsMD has a net margin of 5.34% compared to Alzamend Neuro's net margin of 0.00%. TherapeuticsMD's return on equity of 0.32% beat Alzamend Neuro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TherapeuticsMD	5.34%	0.32%	0.23%
Alzamend Neuro	N/A	-277.74%	-200.07%

TherapeuticsMD has a beta of 0.61, suggesting that its stock price is 39% less volatile than the broader market. Comparatively, Alzamend Neuro has a beta of 0.16, suggesting that its stock price is 84% less volatile than the broader market.

Alzamend Neuro has a consensus price target of $28.00, indicating a potential upside of 1,831.03%. Given Alzamend Neuro's stronger consensus rating and higher probable upside, analysts clearly believe Alzamend Neuro is more favorable than TherapeuticsMD.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TherapeuticsMD	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Alzamend Neuro	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

30.7% of TherapeuticsMD shares are owned by institutional investors. Comparatively, 49.6% of Alzamend Neuro shares are owned by institutional investors. 1.7% of TherapeuticsMD shares are owned by insiders. Comparatively, 1.4% of Alzamend Neuro shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, TherapeuticsMD's average media sentiment score of 0.00 equaled Alzamend Neuro'saverage media sentiment score.

Company	Overall Sentiment
TherapeuticsMD	Neutral
Alzamend Neuro	Neutral

Summary

TherapeuticsMD beats Alzamend Neuro on 9 of the 13 factors compared between the two stocks.

How does Alzamend Neuro compare to Werewolf Therapeutics?

Werewolf Therapeutics (NASDAQ:HOWL) and Alzamend Neuro (NASDAQ:ALZN) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, media sentiment, analyst recommendations, profitability, risk and dividends.

Werewolf Therapeutics' return on equity of -166.99% beat Alzamend Neuro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Werewolf Therapeutics	N/A	-166.99%	-59.88%
Alzamend Neuro	N/A	-277.74%	-200.07%

In the previous week, Werewolf Therapeutics had 1 more articles in the media than Alzamend Neuro. MarketBeat recorded 1 mentions for Werewolf Therapeutics and 0 mentions for Alzamend Neuro. Werewolf Therapeutics' average media sentiment score of 0.00 equaled Alzamend Neuro'saverage media sentiment score.

Company	Overall Sentiment
Werewolf Therapeutics	Neutral
Alzamend Neuro	Neutral

Alzamend Neuro has lower revenue, but higher earnings than Werewolf Therapeutics. Werewolf Therapeutics is trading at a lower price-to-earnings ratio than Alzamend Neuro, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Werewolf Therapeutics	$1.88M	10.21	-$60.82M	-$0.76	N/A
Alzamend Neuro	N/A	N/A	-$8.77M	-$2.90	N/A

64.8% of Werewolf Therapeutics shares are owned by institutional investors. Comparatively, 49.6% of Alzamend Neuro shares are owned by institutional investors. 23.6% of Werewolf Therapeutics shares are owned by insiders. Comparatively, 1.4% of Alzamend Neuro shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Werewolf Therapeutics has a beta of 0.29, meaning that its stock price is 71% less volatile than the broader market. Comparatively, Alzamend Neuro has a beta of 0.16, meaning that its stock price is 84% less volatile than the broader market.

Werewolf Therapeutics currently has a consensus target price of $3.75, indicating a potential upside of 849.37%. Alzamend Neuro has a consensus target price of $28.00, indicating a potential upside of 1,831.03%. Given Alzamend Neuro's higher possible upside, analysts plainly believe Alzamend Neuro is more favorable than Werewolf Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Werewolf Therapeutics	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14
Alzamend Neuro	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Werewolf Therapeutics beats Alzamend Neuro on 10 of the 13 factors compared between the two stocks.

How does Alzamend Neuro compare to Aytu BioPharma?

Alzamend Neuro (NASDAQ:ALZN) and Aytu BioPharma (NASDAQ:AYTU) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, valuation, media sentiment, analyst recommendations, profitability, dividends, institutional ownership and risk.

In the previous week, Alzamend Neuro's average media sentiment score of 0.00 equaled Aytu BioPharma'saverage media sentiment score.

Company	Overall Sentiment
Alzamend Neuro	Neutral
Aytu BioPharma	Neutral

Alzamend Neuro currently has a consensus price target of $28.00, suggesting a potential upside of 1,831.03%. Aytu BioPharma has a consensus price target of $10.75, suggesting a potential upside of 345.87%. Given Alzamend Neuro's higher probable upside, equities analysts plainly believe Alzamend Neuro is more favorable than Aytu BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alzamend Neuro	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Aytu BioPharma	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

Alzamend Neuro has higher earnings, but lower revenue than Aytu BioPharma. Aytu BioPharma is trading at a lower price-to-earnings ratio than Alzamend Neuro, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alzamend Neuro	N/A	N/A	-$8.77M	-$2.90	N/A
Aytu BioPharma	$66.38M	0.39	-$13.56M	-$4.58	N/A

Alzamend Neuro has a beta of 0.16, suggesting that its stock price is 84% less volatile than the broader market. Comparatively, Aytu BioPharma has a beta of 0.25, suggesting that its stock price is 75% less volatile than the broader market.

49.6% of Alzamend Neuro shares are held by institutional investors. Comparatively, 33.5% of Aytu BioPharma shares are held by institutional investors. 1.4% of Alzamend Neuro shares are held by insiders. Comparatively, 4.9% of Aytu BioPharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Alzamend Neuro has a net margin of 0.00% compared to Aytu BioPharma's net margin of -60.17%. Aytu BioPharma's return on equity of -69.93% beat Alzamend Neuro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alzamend Neuro	N/A	-277.74%	-200.07%
Aytu BioPharma	-60.17%	-69.93%	-13.25%

Summary

Alzamend Neuro and Aytu BioPharma tied by winning 6 of the 12 factors compared between the two stocks.

Get Alzamend Neuro News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALZN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALZN vs. The Competition

Export

Metric	Alzamend Neuro	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$6.95M	$3.72B	$7.03B	$12.88B
Dividend Yield	N/A	3.77%	2.58%	10.06%
P/E Ratio	-0.50	9.11	268.67	24.78
Price / Sales	N/A	1,257.67	584.35	95.60
Price / Cash	N/A	44.95	28.89	37.42
Price / Book	7.63	18.03	11.36	6.43
Net Income	-$8.77M	-$13.25M	$3.44B	$347.05M
7 Day Performance	N/A	3.41%	2.10%	0.81%
1 Month Performance	22.88%	-1.44%	-0.34%	-0.79%
1 Year Performance	-39.58%	61.39%	75.23%	21.99%

Alzamend Neuro Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALZN Alzamend Neuro	1.3423 of 5 stars	$1.44 -1.4%	$28.00 +1,844.4%	-37.9%	$6.90M	N/A	N/A	4	Gap Down
BRNS Barinthus Biotherapeutics	3.1516 of 5 stars	$0.61 +6.5%	$4.00 +559.0%	-58.1%	$24.10M	$14.97M	N/A	107	Positive News Earnings Report Gap Up
EVAX Evaxion A/S	2.6792 of 5 stars	$2.86 +2.1%	$11.00 +284.7%	+7.8%	$23.84M	$7.53M	N/A	60	Upcoming Earnings
TXMD TherapeuticsMD	1.157 of 5 stars	$2.05 -0.5%	N/A	+94.4%	$23.72M	$3.02M	34.17	420	Upcoming Earnings
HOWL Werewolf Therapeutics	2.605 of 5 stars	$0.48 +5.7%	$3.75 +689.5%	-67.4%	$23.04M	$1.88M	N/A	40	Upcoming Earnings Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALZN) was last updated on 8/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Alzamend Neuro (ALZN) Competitors

ALZN vs. BRNS, EVAX, TXMD, HOWL, and AYTU

How does Alzamend Neuro compare to Barinthus Biotherapeutics?

Summary

How does Alzamend Neuro compare to Evaxion A/S?

Summary

How does Alzamend Neuro compare to TherapeuticsMD?

Summary

How does Alzamend Neuro compare to Werewolf Therapeutics?

Summary

How does Alzamend Neuro compare to Aytu BioPharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALZN vs. The Competition

Alzamend Neuro Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Alzamend Neuro (ALZN) Competitors

ALZN vs. BRNS, EVAX, TXMD, HOWL, and AYTU

How does Alzamend Neuro compare to Barinthus Biotherapeutics?

Is BRNS or ALZN more profitable?

Do insiders & institutionals believe in BRNS or ALZN?

Which has stronger valuation and earnings, BRNS or ALZN?

Does the media refer more to BRNS or ALZN?

Do analysts prefer BRNS or ALZN?

Which has more risk and volatility, BRNS or ALZN?

Summary

How does Alzamend Neuro compare to Evaxion A/S?

Do institutionals & insiders have more ownership in ALZN or EVAX?

Which has better earnings & valuation, ALZN or EVAX?

Does the media refer more to ALZN or EVAX?

Which has more risk and volatility, ALZN or EVAX?

Is ALZN or EVAX more profitable?

Do analysts rate ALZN or EVAX?

Summary

How does Alzamend Neuro compare to TherapeuticsMD?

Which has preferable earnings & valuation, TXMD or ALZN?

Is TXMD or ALZN more profitable?

Which has more risk & volatility, TXMD or ALZN?

Do analysts recommend TXMD or ALZN?

Do institutionals and insiders believe in TXMD or ALZN?

Does the media refer more to TXMD or ALZN?

Summary

How does Alzamend Neuro compare to Werewolf Therapeutics?

Is HOWL or ALZN more profitable?

Does the media refer more to HOWL or ALZN?

Which has stronger valuation and earnings, HOWL or ALZN?

Do institutionals and insiders have more ownership in HOWL or ALZN?

Which has more volatility & risk, HOWL or ALZN?

Do analysts rate HOWL or ALZN?

Summary

How does Alzamend Neuro compare to Aytu BioPharma?

Does the media favor ALZN or AYTU?

Do analysts recommend ALZN or AYTU?

Which has better valuation and earnings, ALZN or AYTU?

Which has more volatility & risk, ALZN or AYTU?

Do insiders and institutionals hold more shares of ALZN or AYTU?

Is ALZN or AYTU more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALZN vs. The Competition

Alzamend Neuro Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools